Consistent Alterations of Circulating Matrix Metalloproteinases Levels in Untreated Hypertensives and in Spontaneously Hypertensive Rats: A Relevant Pharmacological Target

Basic and Clinical Pharmacology and Toxicology

Volumn 109, Issue 2, 2011, Pages 130-137

  Fontana, Vanessa ^a   Silva, Pamela S ^b   Belo, Vanessa A ^b   Antonio, Raquel C ^a   Ceron, Carla S ^a   Biagi, Celso ^c   Gerlach, Raquel F ^a   Tanus Santos, Jose E ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF CAMPINAS   (Brazil)

^c Santa Casa of Aracatuba   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 MACROGLOBULIN; GELATINASE A; GELATINASE B; NEUTROPHIL COLLAGENASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADULT; ANIMAL MODEL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HYPERTENSION; MALE; NONHUMAN; NORMAL HUMAN; PLASMA; PRIORITY JOURNAL; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; ZYMOGRAPHY;

ADULT; ANIMALS; HUMANS; HYPERTENSION; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 8; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; MIDDLE AGED; RATS; RATS, INBRED SHR; RATS, INBRED WKY;

ANIMALIA; RATTUS;

EID: 79960227472     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2011.00698.x     Document Type: Article

References (45)

1. Bouvet C, Gilbert LA, Girardot D, deBlois D, Moreau P. Different involvement of extracellular matrix components in small and large arteries during chronic NO synthase inhibition. Hypertension 2005;45:432-7.
2. Castro MM, Rizzi E, Figueiredo-Lopes L, Fernandes K, Bendhack LM, Pitol DL et al. Metalloproteinase inhibition ameliorates hypertension and prevents vascular dysfunction and remodeling in renovascular hypertensive rats. Atherosclerosis 2008;198:320-31.
3. Castro MM, Rizzi E, Prado CM, Rossi MA, Tanus-Santos JE, Gerlach RF. Imbalance between matrix metalloproteinases and tissue inhibitor of metalloproteinases in hypertensive vascular remodeling. Matrix Biol 2010;29:194-201.
4. Rizzi E, Castro MM, Prado CM, Silva CA, Fazan R Jr, Rossi MA et al. Matrix metalloproteinase inhibition improves cardiac dysfunction and remodeling in 2-kidney, 1-clip hypertension. J Card Fail 2010;16:599-608.
5. Raffetto JD, Khalil RA. Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem Pharmacol 2008;75:346-59.
6. Chow AK, Cena J, Schulz R. Acute actions and novel targets of matrix metalloproteinases in the heart and vasculature. Br J Pharmacol 2007;152:189-205.
7. Kandasamy AD, Chow AK, Ali MA, Schulz R. Matrix metalloproteinase-2 and myocardial oxidative stress injury: beyond the matrix. Cardiovasc Res 2010;85:413-23.
8. Viappiani S, Sariahmetoglu M, Schulz R. The role of matrix metalloproteinase inhibitors in ischemia-reperfusion injury in the liver. Curr Pharm Des 2006;12:2923-34.
9. Schulz R. Intracellular targets of matrix metalloproteinase-2 in cardiac disease: rationale and therapeutic approaches. Annu Rev Pharmacol Toxicol 2007;47:211-42.
10. Sundstrom J, Vasan RS. Circulating biomarkers of extracellular matrix remodeling and risk of atherosclerotic events. Curr Opin Lipidol 2006;17:45-53.
11. Belo VA, Souza-Costa DC, Lana CM, Caputo FL, Marcaccini AM, Gerlach RF et al. Assessment of matrix metalloproteinase (MMP)-2, MMP-8, MMP-9, and their inhibitors, the tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in obese children and adolescents. Clin Biochem 2009;42:984-90.
12. Goncalves FM, Jacob-Ferreira AL, Gomes VA, Casella-Filho A, Chagas AC, Marcaccini AM et al. Increased circulating levels of matrix metalloproteinase (MMP)-8, MMP-9, and pro-inflammatory markers in patients with metabolic syndrome. Clin Chim Acta 2009;403:173-7.
13. Marcaccini AM, Novaes AB Jr, Meschiari CA, Souza SL, Palioto DB, Sorgi CA et al. Circulating matrix metalloproteinase-8 (MMP-8) and MMP-9 are increased in chronic periodontal disease and decrease after non-surgical periodontal therapy. Clin Chim Acta 2009;409:117-22.
14. Palei AC, Sandrim VC, Cavalli RC, Tanus-Santos JE. Comparative assessment of matrix metalloproteinase (MMP)-2 and MMP-9, and their inhibitors, tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in preeclampsia and gestational hypertension. Clin Biochem 2008;41:875-80.
15. Derosa G, D'Angelo A, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo S et al. Matrix metalloproteinase-2, -9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension. Endothelium 2006;13:227-31.
16. Martinez ML, Lopes LF, Coelho EB, Nobre F, Rocha JB, Gerlach RF et al. Lercanidipine reduces matrix metalloproteinase-9 activity in patients with hypertension. J Cardiovasc Pharmacol 2006;47:117-22.
17. Onal IK, Altun B, Onal ED, Kirkpantur A, Gul Oz S, Turgan C. Serum levels of MMP-9 and TIMP-1 in primary hypertension and effect of antihypertensive treatment. Eur J Intern Med 2009;20:369-72.
18. Yasmin, McEniery CM, Wallace S, Dakham Z, Pulsalkar P, Maki-Petaja K et al. Matrix metalloproteinase-9 (MMP-9), MMP-2, and serum elastase activity are associated with systolic hypertension and arterial stiffness. Arterioscler Thromb Vasc Biol 2005;25:372.
19. Friese RS, Rao F, Khandrika S, Thomas B, Ziegler MG, Schmid-Schonbein GW et al. Matrix metalloproteinases: discrete elevations in essential hypertension and hypertensive end-stage renal disease. Clin Exp Hypertens 2009;31:521-33.
20. Tayebjee MH, Nadar S, Blann AD, Gareth Beevers D, MacFadyen RJ, Lip GY. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). Am J Hypertens 2004;17:764-9.
21. Ahmed SH, Clark LL, Pennington WR, Webb CS, Bonnema DD, Leonardi AH et al. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation 2006;113:2089-96.
22. Zervoudaki A, Economou E, Pitsavos C, Vasiliadou K, Aggeli C, Tsioufis K et al. The effect of Ca2+ channel antagonists on plasma concentrations of matrix metalloproteinase-2 and -9 in essential hypertension. Am J Hypertens 2004;17:273-6.
23. Li-Saw-Hee FL, Edmunds E, Blann AD, Beevers DG, Lip GY. Matrix metalloproteinase-9 and tissue inhibitor metalloproteinase-1 levels in essential hypertension. Relationship to left ventricular mass and anti-hypertensive therapy. Int J Cardiol 2000;75:43-7.
24. Gerlach RF, Demacq C, Jung K, Tanus-Santos JE. Rapid separation of serum does not avoid artificially higher matrix metalloproteinase (MMP)-9 levels in serum versus plasma. Clin Biochem 2007;40:119-23.
25. Gerlach RF, Uzuelli JA, Souza-Tarla CD, Tanus-Santos JE. Effect of anticoagulants on the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities. Anal Biochem 2005;344:147-9.
26. Gerlach RF, Meschiari CA, Marcaccini AM, Palei AC, Sandrim VC, Cavalli RC et al. Positive correlations between serum and plasma matrix metalloproteinase (MMP)-2 or MMP-9 levels in disease conditions. Clin Chem Lab Med 2009;47:888-91.
27. Souza-Tarla CD, Uzuelli JA, Machado AA, Gerlach RF, Tanus-Santos JE. Methodological issues affecting the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities. Clin Biochem 2005;38:410-4.
28. Woessner JF Jr. Matrix metalloproteinase inhibition. From the Jurassic to the third millennium. Ann N Y Acad Sci 1999;878:388-403.
29. Martinez ML, Castro MM, Rizzi E, Fernandes K, Demacq C, Bendhack LM et al. Lercanidipine reduces matrix metalloproteinase-2 activity and reverses vascular dysfunction in renovascular hypertensive rats. Eur J Pharmacol 2008;591:224-30.
30. Martinez ML, Rizzi E, Castro MM, Fernandes K, Bendhack LM, Gerlach RF et al. Lercanidipine decreases vascular matrix metalloproteinase-2 activity and protects against vascular dysfunction in diabetic rats. Eur J Pharmacol 2008;599:110-6.
31. Demacq C, de Souza AP, Machado AA, Gerlach RF, Tanus-Santos JE. Genetic polymorphism of matrix metalloproteinase (MMP)-9 does not affect plasma MMP-9 activity in healthy subjects. Clin Chim Acta 2006;365:183-7.
32. Blankenberg S, Rupprecht HJ, Poirier O, Bickel C, Smieja M, Hafner G et al. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 2003;107:1579-85.
33. Timms PM, Mannan N, Hitman GA, Noonan K, Mills PG, Syndercombe-Court D et al. Circulating MMP9, vitamin D and variation in the TIMP-1 response with VDR genotype: mechanisms for inflammatory damage in chronic disorders? QJM 2002;95:787-96.
34. Flamant M, Placier S, Dubroca C, Esposito B, Lopes I, Chatziantoniou C et al. Role of matrix metalloproteinases in early hypertensive vascular remodeling. Hypertension 2007;50:212-8.
35. Lacchini R, Jacob-Ferreira AL, Luizon MR, Coeli FB, Izidoro-Toledo TC, Gasparini S et al. Matrix metalloproteinase 9 gene haplotypes affect left ventricular hypertrophy in hypertensive patients. Clin Chim Acta 2010;411:1940-4.
36. Lacchini R, Jacob-Ferreira AL, Luizon MR, Gasparini S, Ferreira-Sae MC, Schreiber R et al. Common matrix metalloproteinase 2 gene haplotypes may modulate left ventricular remodelling in hypertensive patients. J Hum Hypertens 2011;doi: [Epub ahead of print].
37. Mannello F, Tanus-Santos JE, Meschiari CA, Tonti GA. Differences in both matrix metalloproteinase 9 concentration and zymographic profile between plasma and serum with clot activators are due to the presence of amorphous silica or silicate salts in blood collection devices. Anal Biochem 2008;374:56-63.
38. Mannello F, Tonti GA, Tanus-Santos JE, Gerlach RF. Silicate increases the release of MMP-9 forms in peripheral blood: why gelatin zymography differs significantly in citrate plasma and serum obtained with or without clot activators. Clin Chem 2007;53:1981-2.
39. Ceron CS, Castro MM, Rizzi E, Montenegro MF, Fontana V, Salgado MC et al. Spironolactone and hydrochlorothiazide exert antioxidant effects and reduce vascular matrix metalloproteinase-2 activity and expression in a model of renovascular hypertension. Br J Pharmacol 2010;160:77-87.
40. Tran ED, DeLano FA, Schmid-Schonbein GW. Enhanced matrix metalloproteinase activity in the spontaneously hypertensive rat: VEGFR-2 cleavage, endothelial apoptosis, and capillary rarefaction. J Vasc Res 2010;47:423-31.
41. Chung AW, Booth AD, Rose C, Thompson CR, Levin A, van Breemen C. Increased matrix metalloproteinase 2 activity in the human internal mammary artery is associated with ageing, hypertension, diabetes and kidney dysfunction. J Vasc Res 2008;45:357-62.
42. Spiers JP, Kelso EJ, Siah WF, Edge G, Song G, McDermott BJ et al. Alterations in vascular matrix metalloproteinase due to ageing and chronic hypertension: effects of endothelin receptor blockade. J Hypertens 2005;23:1717-24.
43. Tuomainen AM, Nyyssonen K, Laukkanen JA, Tervahartiala T, Tuomainen TP, Salonen JT et al. Serum matrix metalloproteinase-8 concentrations are associated with cardiovascular outcome in men. Arterioscler Thromb Vasc Biol 2007;27:2722-8.
44. Nagase H, Itoh Y, Binner S. Interaction of alpha 2-macroglobulin with matrix metalloproteinases and its use for identification of their active forms. Ann N Y Acad Sci 1994;732:294-302.
45. Chang HR, Yang SF, Li ML, Lin CC, Hsieh YS, Lian JD. Relationships between circulating matrix metalloproteinase-2 and -9 and renal function in patients with chronic kidney disease. Clin Chim Acta 2006;366:243-8.